Field of Science

Edward Witten, chemistry and the problems with falsification

Science writer and journalist John Horgan who wrote the notorious and thought-provoking book "The End of Science" in the 90s has an interesting interview with theoretical physics giant Edward Witten. Witten, who won the Fields Medal back in the 80s, is widely regarded because of his huge status and influence as one of the main reasons a number of physicists switched to doing string theory in the 90s.

The whole interview is worth reading but there was one chemistry-related response that Witten gave which especially caught my eye:

Horgan: Do you agree with Sean Carroll that falsifiability is overrated as a criterion for distinguishing science from pseudo-science? 
Witten: Scientists aim to get as reliable and precise an understanding of nature as we can.  The gold standard is a precise prediction that can be tested in a precise way in a laboratory experiment.  Experiments that disprove theories are an important part of the scientific process. 
With that said, it is a little too narrow to claim that science consists of trying to falsify theories because a lot of science consists of trying to discover things. (Chemists who attempt a new synthesis could say they are trying to falsify the hypothesis that this new synthesis won’t work.  But that isn’t what they usually say.  People who search for life on Mars could say they are trying to falsify the hypothesis that there is no life on Mars. Again, people don’t usually talk that way.)
I have to give credit to Witten for pointing out the problems with falsifiability in the context of chemistry; in my experience there's not even too many chemists who talk about this rather central aspect of the science. The most prominent one who does is Roald Hoffmann who in his recent collection of essays (which I reviewed for Nature Chemistry) does analyze the issues with using falsifiability as a significant criterion in the philosophy of chemistry. Hoffmann also points to other well-known constructs from the philosophy of science, such as hypothesis testing, as being insufficient guides in understanding the methodology of chemistry.

As both Hoffmann and Witten point out, most chemists when they are trying to make molecules are not really trying to falsify anything, except in the trivial and general sense of trying to "falsify" the basic principles of chemistry. But this fact also goes to the heart of chemistry as a science and art that is more akin to architecture and which really tries to build things rather than simply breaking them down. That is also the reason why, in my opinion, the whole reductionist paradigm has some clear limitations when applied to chemistry; most chemists are really trying to see how emergent molecular properties arise from putting atoms together in different arrangements. Breaking things down in the form of elemental or spectroscopic analysis is of course a reductionist activity that's an essential part of chemistry, but even that process really is in service to understanding how atoms can combine together to give rise to novel structure and function.
It's good to have even physicists like Witten point this out. But it's also something that more chemists and chemistry popularizers should be aware of, especially when they describe their philosophy of doing science to the wider world. Explicating the unique philosophy of chemistry not only sheds light on why chemistry is different in its own way but also demonstrates why we must not hold exalted notions from the philosophy of science like falsification sacrosanct.

The 2014 Nobel Prize in Chemistry and tool-driven scientific revolutions

Image: Nobelprize.org
Last year I wrote a post detailing the views of historian Peter Galison and physicist Freeman Dyson of science as being as much of a tool-driven revolution as an idea-driven one. Now here's a great instance of that tool-driven paradigm change: this year's Nobel prize for chemistry which was awarded to Eric Betzig, Stefan Hell and W. E. Moerner for single molecular techniques, especially single molecule fluorescence microscopy and spectroscopy. The prize has been awarded for a set of techniques - and technological developments - rather than for a groundbreaking idea. But these techniques have led to ideas which hold enormous promise for the future. The recognition thus reflects how ideas and tools feed off of each other in science.

Moerner seems to have been an obvious choice on several people's lists for years while Hell and Betzig seem to have largely escaped attention. 

Here's what the three prizewinners did, in a nutshell:
Two separate principles are rewarded. One enables the method stimulated emission depletion (STED) microscopy, developed by Stefan Hell in 2000. Two laser beams are utilized; one stimulates fluorescent molecules to glow, another cancels out all fluorescence except for that in a nanometre-sized volume. Scanning over the sample, nanometre for nanometre, yields an image with a resolution better than Abbe’s stipulated limit. 
Eric Betzig and William Moerner, working separately, laid the foundation for the second method, single-molecule microscopy. The method relies upon the possibility to turn the fluorescence of individual molecules on and off. Scientists image the same area multiple times, letting just a few interspersed molecules glow each time. Superimposing these images yields a dense super-image resolved at the nanolevel. In 2006 Eric Betzig utilized this method for the first time.
The whole suite of single molecule techniques have huge implications for imaging, tracking and tagging molecules of all kinds, but especially so in biology. The importance of fluorescence and spectroscopy for biology have been recognized for years (as exemplified by the Nobel Prize in 2008 and 2002 for instance) but today's prize brings those techniques together and applies them to individual molecules. The prize is not only eminently well-deserved but heralds several prizes of this sort in the future as these techniques are applied to important and promising areas like neuroscience and drug discovery. In addition it is a truly interdisciplinary recognition bringing together physics, chemistry and biology. Which means that everyone should celebrate (or complain...).

There are a few interesting tidbits associated with the three scientists and their work. It seems like both Hell and Betzig were sort of in the wilderness when they made their original pioneering contributions. Hell was working in Finland, away from the mainstream research centers when he had the idea for beating the diffraction limit. And in a trend that's more common than we think, his 2000 paper on STED was rejected by Science and Nature and accepted in PNAS.

Betzig's story is especially interesting: He left academia in 1996 and worked at his father's machine tool company for several years, developing hydraulic technology which was commercially unsuccessful. But the single molecule fluorescence bug had bitten him too hard to let go, so through a series of ventures - one of which involved building a single molecule instrument with a friend in the friend's living room - he gradually returned back to academia, settling in at the Janelia Research Farm Campus in Virginia. My suspicion is that those years dabbling in technology and industry were exactly what enabled Betzig to develop his engineering acumen and apply it to building the right tools.

It's also interesting to note that both Betzig and Moerner made their original pioneering discoveries in industry - Moerner when he was working at IBM in San Jose and Betzig when he was working in his own private company. I think their stories send a clear message that interesting ideas - and especially their implementation - come quickest when good pure science collides with the kind of good engineering and practical expertise that one is exposed to in industrial settings. I think the 2014 chemistry Nobel Prize recognizes engineering as much as science and this makes it an especially important example of a tool-driven scientific revolution.

In any case, an eminently well-deserved prize with implications that are just starting to be realized and which will undoubtedly scale many new horizons in the future. Congratulations to the three prizewinners!

Updated #chemnobel odds for tomorrow

So today's physics Nobel Prize was awarded to three physicists who worked on blue LEDs, devices that make light bulbs glow brighter and last longer than normal ones. It's a well-deserved recognition, really one for a physics-based invention rather than for a fundamental discovery (as an aside, it's worth noting how much the invention owes to the chemistry of gallium nitride semiconductors). The last time an invention was recognized was when the prize was given out for CCDs in 2009.

However I think the prize also casts some serious doubt on a lot of predictions that Thomson Reuters and others have been making for tomorrow's chemistry award. It's certainly not unheard of for prizes in two disciplines to be awarded for the same field of study (for instance chemistry and medicine often trail each other in the context of crystal structures of important proteins) and I haven't really done an exhaustive study of how often this has happened before, but I would guess that the odds of it are pretty low.

If nothing else, today's blue LED prize almost certainly means that one of the most popular predictions for tomorrow (and Thomson Reuters's choice) - that for Ching Tang's work on organic LEDs - will have to be tossed out of the window for now. It seems extremely unlikely for two kinds of LEDs to be awarded two different prizes in the same year.

Today's recognition is not just a recognition of materials science but even more so of energy. That might mean that some of the energy-based prize predictions for tomorrow may also be off the mark. Thus, the odds for awarding a prize for Li-ion batteries or for dye injected solar cells may sadly have worsened.

Since both materials and energy are no longer looking that great in my book, I now have a revised set of predictions. In light of today's development I think that the chances for other kinds of chemistry might now be higher. So I am now bumping up my predictions for biochemistry (click chemistry, nuclear receptors, chemical biology - eg. Stuart Schreiber) and also adding a prediction for polymers (especially ATRP) which I missed earlier. Single molecule spectroscopy (Moerner etc.)  and electron transfer in proteins and biomolecules (Gray, Barton etc.) also stand a good chance now.

Chemists, time to break out the pitchforks: A biologist may "steal" "our" Nobel once again...

Maryland Congressman asks the NIH to fund more young scientists

Maryland Congressman Andrew Harris
Now here's something that you don't get to see everyday - a politician taking (the right kind of) interest in the NIH's activities and asking the agency to support the most important ideas in basic biomedical research by funding young scientists. Maryland Congressman Andrew Harrison's thesis is that whatever money the NIH might have left after all the funding cuts is being spent on scientists in their 40s and beyond; he is mostly alluding to the depressing fact that most academic researchers now receive their first big RO1 grant at the age of 42. Harris says this is a mistake.

The problem, as he sees it, is that cutting-edge science is a young man's game, and it is also unlikely to be the game of someone who has already achieved his or her biggest hits:

"Every year the National Institutes of Health receives almost $30 billion in federal funds to invest in biomedical research. The bulk of that money goes to researchers who are in many cases esteemed in their fields — but also, in many cases, beyond the age when most scientists make their most important contributions to their fields.  
A study for the National Bureau of Economic Research from 2005 examined the age at which over 2,000 Nobel Prize winners and other notable scientists in the 20th century came up with the idea that led to their breakthrough. Most were between 35 and 39. Yet the median age of first- time recipients of R01 grants, the most common and sought-after form of N.I.H. funding, is 42, while the median age of all recipients is 52. More people over 65 are funded with research grants than those under age 35."
The Congressman makes another two observations that are cogent; first, that the NIH often funds glamorous research at the expense of more basic research, and second, that the NIH also seems to fund interesting projects that nonetheless seem far less important than research into humanity's most pressing problems like Alzheimer's disease.
"For many fields, particularly those that don’t have immediate commercial applications or sex appeal for grant-making nonprofit groups, the N.I.H. is a vital source of money. We’ll never know what breakthroughs were missed because young investigators were not provided with the resources necessary to pursue unique ideas over the last 15 years. They may have had the idea that would have led to a cure for ovarian cancer, Alzheimer’s disease or pediatric cardiomyopathy. 
...Today we see too many grants going to things like creating a video game for moms to teach them how to get their kids to eat more vegetables, or studying the creation of a social security system in southern Mexico. Such projects may have value to some, but is creating a video game really more important than researching a cure for Alzheimer’s?"
I have no problem seeing where Harris is coming from - the paucity of funds for young scientists is one of the biggest barriers for newly minted PhDs to consider academic research these days - but I am not sure the "young is great" theme applies as much to biomedical researchers as to, say, theoretical physicists. In fact a study which I blogged about a few years ago pointed out that because their work involves raw brain power more than anything else, theoretical physicists are the most likely to produce great breakthroughs in their 20s and early 30s; no wonder that the physics done by young Turks like Paul Dirac and Werner Heisenberg was called 'Knabenphysik' - the physics of youth.

As that study indicated however, with experimental sciences like biomedical research things are different, and many biomedical breakthroughs came from scientists at a relatively advanced age. There has been no synthetic organic chemist winning the Nobel Prize in his or her 20s for instance, and even the great Robert Burns Woodward - widely considered to be a true prodigy in chemistry if there ever was one - had to wait until his 40s to be recognized. When it comes to sciences like organic chemistry or molecular biology it's not a question of raw IQ; it's a question of spending those 10,000 hours to learn the tricks of laboratory manipulation, to assimilate the existing literature and, because of the great complexity of biological systems, to develop a feel for their workings. This inevitably takes time, even for very smart people.

Thus while I think Harris's heart is in the right place and we undoubtedly need more grants for young people, the real strategy should be to fund interesting ideas irrespective of age. I fear that Harris's proposal, if carried out to its logical conclusion, might achieve the opposite effect - it might alienate older researchers who are still very much capable for bright ideas. To fund the best science, all we have to do is to fund the best science.

Note: I did not even notice until much later that the Congressman is Republican. This gives me hope that I haven't turned one hundred percent cynical yet.

The hidden dangers of HIV

HIV particles swarming the defenses of a macrophage
I have written a few times about the myriad obstacles thwarting our efforts to design drugs against pressing medical problems, but perhaps none are as formidable as some of the challenges that evolution itself has set up for us. A disturbing example of this challenge in the context of HIV treatment is described by the husband and wife team of Robert and Janet Siliciano at Johns Hopkins in a recent Science perspective. The article talks about why a "cure" for AIDS may be far more difficult than we thought. It comes on the heels of the much-hyped 'Mississippi Baby', an infant who was thought to be 'cured' but who turned out to still harbor the infection. As of now the only known HIV-free human being is the remarkable so-called 'Berlin patient', but articles like these make even his case one of cautious optimism.

The authors focus on a troubling discovery made in the late 90s, around the same time that the new HIV protease inhibitors were leading to a striking decrease in the death rate. It was found that even when these drugs were effective, they were still unable to kill all the virus because some of the virus essentially went into hiding in the form of a latent state in which it integrates its DNA in 'resting' CD4 cells. This latent reservoir of hidden virions is like a Trojan horse full of deadly warriors, waiting to regroup and rebound after infection kills all the 'visible' viral particles and is discontinued for reasons of side effects or patient compliance. Ironically in this process, as biologist Alison Hill from Harvard explains in a helpful NOVA article about purported HIV 'cures', the virus is actually taking advantage of T cells' usually helpful property to preserve the 'memory' of infections and get reactivated.

But this reservoir of hidden HIV is why, in spite of early hopes, it has been impossible to completely eradicate the virus even when its levels in the blood become undetectable. Interestingly in the Science article the Silicianos make it clear that the problem is not one of lack of sensitive detection methods - the current methods are good enough to detect even a single latent cell in principle - but that of sampling, that is, getting enough tissue from the right places to detect the virus. The ultimate problem is that in the absence of detection of this latent reservoir, we will always be stuck with having the infection remerge even when treatments purportedly have rendered it undetectable.

From a drug discovery standpoint there is some hope. As long ago as the late 90s scientists were trying to adopt a 'shock and kill' strategy in which they tried to essentially smoke the virus out of hiding and the  neutralize it. But early efforts to do this involved administering large doses of interleukins, which basically put the immune system into overdrive and caused some very unpleasant reactions. Since then many other potential therapies, most notably histone deacetylase inhibitors, have been tried in order to get the resting viral DNA to reactivate itself. 

Another promising treatment that the article does not mention comes from Paul Wender's laboratory at Stanford. Wender and a few others have found out that a natural product from the American Samoan Mamala tree called prostratin can reactive latent and kill HIV at very low concentrations; in fact from what I can tell, prostratin was first described by researchers from the NCI in the Journal of Medicinal Chemistry as far back as 1992. Pre-clinical studies are underway (if successful, this would almost be a fairy tale story of drugs from nature, akin to that of taxol). Finally, a paper that just came out in Cell last week talks about using a combination of drugs like histone deacetylase inhibitors to smoke the virus out of hiding and then using antibodies against the glycoprotein envelope of the virus to finally silence it.

The hope is that some or all of these therapies - small molecules to force the virus out of hiding and a combination of small molecules and antibodies to kill it and potentially render immunity to further infection - will at some point work. There is always the issue of how tolerable the side effects of these combination therapies will be. But more than anything else, the complex challenge illustrates both the necessity of researchers from different fields adopting a variety of strategies to fight AIDS as well as the formidable barriers that the virus has set up for us. 

Ultimately as the article says though, an achievable goal might be more modest; we might be able to keep patients on and off treatment for long enough so that they can live normal lives in spite of potential viral rebound. Even that chronic treatment scenario will be a great achievement, no less attractive than a mythical 'cure'.

Image: Wikipedia.

Prof. Erland Stevens's online medicinal chemistry course

This spring I had a post up about an online medicinal chemistry course taught by Prof. Erland Stevens of Davidson College. It looks like the course was received quite well, with 14,000 students signing up. Now it's going to be taught again, starting from October 13th. Here's some information about the course that Prof. Stevens sent along; from the list of topics it seems to cover most major aspects of the basic principles and practice of drug discovery from a chemistry perspective. Would definitely recommend it.

  • The edX course (Medicinal Chemistry) starts October 13th and runs eight weeks
  • Cost: free with both free and for-pay certification options
  • Prerequisites: general chemistry (binding energies, intermolecular forces), some organic chemistry (line-angle structures and functional groups), knowledge of cell parts and functions, comfort with logarithmic and exponential equations
  • Time required: 1 hour of video per week, completing all assignments will require approx. 1 hour per day
  • Topics (appox. 1 wk each)
    (1) drug approval process (early drugs, clinical trials, IP factors)
    (2) enzymes and receptors (inhibition, Ki, types of ligands, Kd)
    (3) pharmacokinetics (Vd, CL, compartment models)
    (4) metabolism (phase I and II, genetic factors, prodrugs)
    (5) molecular diversity (drug space, combi chem, libraries)
    (6) lead discovery (screening, filtering hits)
    (7) lead optimization (FG replacements, isosteres, peptidomimetics)
    (8) important drug classes (selected examples)
  • Target audience: anyone with an interest in the structural basis of how drugs are designed

It's the most wonderful time of the year...#2014Nobels


...and the carolers are already out. Thomson Reuters already have their 2014 Nobel Prize prediction list, and past tradition obliges me to respond. C&EN is also having a nice panel discussion on the prize at 3:30 PM EDT on September 30th, so if you want to contribute to the chest-thumping/eye-gouging polite discussion feel free to join.

I was of course quite tickled when my own field won the prize last year so I think it's safe to discount a theoretical or computational chemistry prize from being given out this year (I am thinking of you, David Baker; you'll just have to wait). Contrary to there being absolutely no evidence to support this, I continue to believe that the prize committee does try to preserve a modicum of diversity, so that they don't end up recognizing similar areas every year.

This year I will keep my list short. The past ten years have recognized theoretical/computational chemistry (1 out of 10), biochemistry/bioorganic chemistry (5 out of 10!), organic synthesis (2 out of 10), surface chemistry (1 out of 10) and quasicrystals (1 out of 10) so I am going to be partial to other fields this time. 

Top of my list is John Goodenough for being a co-developer of the lithium-ion battery. I have thought for a while now that this is a prize that has probably been neglected because it's too obvious (remember the prize for IVF?). But that's precisely what makes it so important; lithium-ion batteries are everywhere. Giving a prize for batteries will also be a recognition of the growing importance of energy, and especially non-fossil fuel based energy. Another way to recognize the importance of energy would be to award a prize to Michael Grätzel for the dye-sensitized solar cell.

Speaking of electrochemistry, other often cited names are those of Allen Bard and Harry Gray who have devoted their careers to studying electron transfer, albeit in different kinds of systems (Gray mainly in proteins). The last electron transfer prize was given out to Rudolf Marcus in 1992 so its time may be due. Personally I think that the work that Bard and Gray have done is undoubtedly fascinating and important, but I am a little skeptical about whether its broadly applicable enough to get top billing from the Nobel committee.

Another favorite of mine for this year is Ching Tang of the University of Rochester who made key contributions to the organic light-emitting diode (LED). Like the lithium-ion battery the organic LED is also a mainstay of modern life so saluting its utility would be no surprise. There is also a chance that this contribution could be poached by the physicists. Thomson Reuters also has Tang on their list and he has received the 2011 Wolf Prize, which is almost as good as getting a Nobel.

Turning to what I think are less probable but still attractive choices, I think dendrimers (Frechet) and click chemistry (Sharpless) might stand a chance; the former more than the latter in terms of its longer life and more extensive validation in chemistry. Metal-organic frameworks (Yaghi and others) are also probably validated and used enough to be recognized. I don't really see a straight prize for organic synthesis or methodology, partly because two methodology prizes (palladium-catalyzed reactions and metathesis) have been awarded in the last decade. I would love to see a chemistry/medicine prize awarded to Carl Djerassi for his invention of the pill, but I increasingly get the feeling that that ship has sailed for good.

So that's my personal list for this year's chemistry prize - energy as a field is at the top, and LEDs, batteries and electron transfer are my favorite contenders.

Occasionally the prizes for chemistry and medicine overlap so it's worth speculating a bit on the medicine prize. In the "obvious" category are people like Alec Jeffreys (DNA fingerprinting), Leroy Hood and Craig Venter (the nuts and bolts of gene sequencing), Robert Langer (drug delivery) and a longstanding favorite of many people - nuclear receptors (Chambon and Evans; Elwood Jensen sadly passed away in 2012). Thomson Reuters is proposing David Julius who did important work on figuring out the receptors responsible for pain, and that seems like a good choice to me. More speculatively, I feel convinced that there are prizes for CLARITY and CRISPR sometime in the future, but not yet.

Although I can't predict who will win, one thing that I think we can all bet on is that someone will be woken up at the crack of dawn by a phone call, someone will inevitably be left out, and someone's ardent belief in the possibility that his or her favorite scientist was somehow hijacked by a rival field will be shored up by another data point.

I will make a list of other predictions as I hear them.

Update: Here's Everyday Scientist and here's the Pipeline.

What if the Manhattan Project had been like an Alzheimer's disease drug discovery project

The vast K-25 gaseous diffusion plant at Oak Ridge - an
engineering endeavor (Image: Nuclear Secrecy Blog)
Every once in a while you will find someone comparing a major scientific or technological challenge to the Manhattan Project - among such comparisons would be the Human Genome Project and the Brain Map Initiative. It's also not unheard of for drug discovery being uttered in the same breath as the Manhattan project; for instance administrators and scientists have been calling for new antibiotic discovery to be placed on the same footing as the wartime quest to build the first atomic bomb.

To be honest, most of these comparisons obfuscate more than they instruct. It's not that they are entirely invalid, but their core kernels of truth significantly differ.

To see why, let's compare a typically challenging, novel drug discovery project like finding a cure or mitigating therapy for Alzheimer's disease to designing Fat Man or Little Boy. The mandate for the Manhattan Project was, "produce a practical military weapon that works by harnessing energy from nuclear fission of uranium or plutonium". The mandate for Alzheimer's disease would be "discover and develop a small molecule that mitigates or cures the symptoms of Alzheimer's disease and that is potent, safe, enters and exits the body in a reasonable period of time and causes minimal side effects".

The first thing to notice is the difference between the word "produce" and "discover". Manhattan was not a discovery project, and the word "produce" in fact appeared in the first line of 'The Los Alamos Primer', the indoctrination lectures given by physicist Robert Serber at the beginning of the adventure. Production is more akin to engineering than science, so that word sets the tone for the entire project. That is not to say that Manhattan did not involve science and scientists - of course it did. But the key thing to realize is that the basic discovery part of the science had been done between 1938 and 1942. This part was symbolized by four milestones: the discovery of fission in December 1938 by Hahn and Strassmann, the first 'proof of principle' calculations by Frisch and Peierls in March 1940 indicating the feasibility of a fission weapon, the working out of the actual mechanism and effects of a bomb in the summer of 1942 by Oppenheimer and his associates at Berkeley and the successful initiation of a nuclear chain reaction by Fermi and his associates in Chicago in December 1942. By the time the project started in March 1943, the atomic constitution of matter was thus firmly mapped and the elementary particles which were required to harness fission were all discovered and their properties charted as either 'known knowns' or 'known unknowns'.

The major challenges associated with the project were thus not discovery challenges. It was fully known by the beginning of the project that if you suddenly bring a sufficiently large lump of highly purified uranium-235 together you would cause a very big bang. The key words there were 'large', 'purified' and 'suddenly' and these words really signaled the enormous engineering challenges. To produce a large and purified lump of uranium or plutonium would take vast chemical and engineering complexes in Oak Ridge, TN and Hanford, WA which employed hundreds of thousands of workers and whose use of resources like electricity and copper would rival the size of the US automobile industry. That was really mostly engineering, the unimaginably strenuous application of man and machine in separating two isotopes from each other and in creating a novel element.

The 'sudden' part of the challenge was equally important and again heavily steeped in engineering. For the uranium bomb this was not a big issue since a heavy modified gun would do the job. The really novel find - and this would be classified as a discovery, albeit of an applied kind - was the mechanism of a plutonium weapon. In the summer of 1944 it was realized for good that given the spontaneous rate of fission of Pu-240 which was contaminating the samples of Pu-239 produced in the Hanford reactor, a gun-type weapon that would work for uranium would simply cause an equivalent plutonium weapon to pre-detonate. The solution circumventing this problem - implosion using shaped 'lenses' - was probably the most novel discovery/invention to come out of the Manhattan Project. The novelty of this solution was why they tested the plutonium bomb in July 1945 but not the uranium bomb. In fact implosion could be considered to be the one truly novel 'secret' to come out of the project.

But again, putting implosion into practice was almost completely engineering. Brilliant scientists like John von Neumann did contribute in calculating how you would get a perfectly symmetrical, inward-looking shock wave to compress the plutonium core, but the key challenges were designing and fashioning the explosive lenses - layered arrangements of slow and fast-burning plastic charges that would alternately diverge and then precisely converge a shock wave - that would make implosion possible as well as crafting detonators that would fire simultaneously on the surface of the weapon to send the shock waves in. To that end the metallurgists and chemists at Los Alamos were put to work refining these plastic arrangements from hot molds, shaping them and smoothing out even the tiniest air imperfections in the form of bubbles that would cause the shock waves to deviate from perfect symmetry. Similarly experts in electronics were put to work inventing new timing systems for detonators. This work was all chemistry, chemical engineering, electronics and machine shop. It involved not exalted, Nobel Prize-winning minds but the most practical minds, minds which sometimes lacked even a college degree but which could work wonders with their hands (one of these minds happened to be that of David Greenglass, the spy who shuttled secrets to Klaus Fuchs). In fact this part of the project was so important that much of the details are still classified, and rightly so. Master the design of explosive lenses and you command the explosive consequences of plutonium.

The culmination of all this engineering and science is well known, but the tone for that was set in 1943. No wonder Richard Feynman, when describing the Manhattan Project in his memoirs, called it "not science, mostly engineering". He was right.

Now what if the Manhattan Project had been like a novel drug discovery project for Alzheimer's disease? The physicists working on it would still be in the dark ages. The equivalent of fission in Alzheimer's would be the mechanism(s) that causes it, both on the molecular level and on a more global level. We don't know that yet. The Alzheimer's equivalent of protons, neutron and electrons would be the molecular or epidemiological components that cause the disease. There are scattered clues about them, but we really don't know those yet either. Consider the rogue, misfolded protein Aß (amyloid beta) for instance: ten years ago it was regarded as possibly the major culprit in the disease; now it is regarded simply as something associated with the disease in a major way, but nobody knows exactly how. Every major clinical trial that promises to target interesting mechanisms and components in Alzheimer's has failed miserably over the last few years, which is probably not too surprising if we were in ignorance of the real molecular components and were targeting the wrong mechanisms to begin with. 

And even if we knew the mechanisms and the components, the ensuing development of an Alzheimer's drug is no mere engineering challenge. That's because even the most basic processes of drug discovery - things like getting drugs across cell membranes or even getting them to dissolve in an aqueous solution - are too poorly understood to be able to be predicted accurately. Thus, the engineering part of drug discovery is far more tied to a woefully deficient understanding of the science than the engineering part for the Manhattan Project was. The implication of this is that because prediction is largely futile, we have to test tens of thousands of candidates in drug discovery to see what works: What if the Manhattan project needed to build thousands of bomb prototypes to find the one that finally worked? The difference between bomb design and drug design is thus not one of manpower, resources or engineering; it is one of a basic lack of information and deep, dark patches of ignorance. And it arises from the fundamental complexity of biological systems compared to engineering systems.

Thus, if the Manhattan Project were truly an Alzheimer's disease drug discovery project, the physicists working on it would have started not knowing about nuclear fission and not even knowing about protons, neutrons and electrons, let alone about cross sections or plutonium. Here's what their mandate would have looked like then: "Discover what stuff is made up of. Find if any of it can be manipulated to release large amounts of energy. And if you find this, then try to figure out if you can get enough of this special material to make a practical military weapon." In other words, there probably would not have been a mandate to build an atomic bomb in the first place.

However I am ready to take bets on whether this mandate - given to all those brilliant minds in 1942 - would have led to Little Boy or Fat Man by 1945.

Afterthought: So if the Manhattan Project was in fact mostly engineering, it's worthwhile asking why it's associated with science and scientists - and especially physics as opposed to chemistry which was equally important - in the public imagination. I believe the answer in one word is 'myth-making'. Men like Feynman and Oppenheimer are considered so brilliant and fascinating that they have inevitably come to stand in for the whole project.

Other posts on the complexities of biology and the futility of comparing drug discovery with engineering challenges or physics:

1. Why chemistry (and biology) is not physics.
2. Why drug design is like airplane design. And why it isn't.
3. Derek Lowe on what he calls the 'Andy Grove Fallacy': 1, 2.
4. Why it's hard to explain drug discovery to physicists.

Happy Birthday to the man who found life slipping away from his fingers



“In my quest for the secret of life I started my research in histology. Unsatisfied by the information that cellular morphology could give me about life, I turned to physiology. Finding physiology too complex, I took up pharmacology. Still finding the situation too complicated, I turned to bacteriology. But bacteria were even too complex, so I descended to the molecular level, studying chemistry and physical chemistry. After twenty years' work, I was led to conclude that to understand life we have to descend to the electronic level and to the world of wave mechanics. But electrons are just electrons and have no life at all. Evidently on the way I lost life; it had run out between my fingers.”
This quote comes from Albert Szent-Gyorgyi - born 121 years ago today. Gyorgyi was a Hungarian biochemist and Nobel Laureate who discovered vitamin C and worked out many of the components of what we now call the Krebs cycle. 

His quote is the best encapsulation I know of the limitations of reductionism, and of the non-reduction of biology to physics in particular. Szent-Gyorgyi zeroes in on the essential problem; as we drill down from unquestionably living cells to molecules to unquestionably non-living individual electrons, life somehow slips away sometime during the transition from between our microscopes, pipettes and petri dishes.

At what point it exactly does this and how is a quest that will continue to occupy us for as long as there is a human mind capable of scientific reflection.

Happy Birthday to the man with five brains

Today is Murray Gell-Mann's birthday. John Brockman calls him "the man with five brains, each one of which is smarter than yours". We are thankful he is still with us and holding forth on a variety of important problems. Gell-Mann of course is famous as the man who, inspired by a line from a book which he predictably would be the right person to have read, invented quarks. Nobody has observed an isolated quark yet, but there have been plenty of Nobel Prize-winning experiments confirming their evidence through other incontrovertible means.

In the 1960s there was a famous running rivalry between Gell-Mann and Richard Feynman for the title of Smartest Man on the Planet (there was another lesser known rivalry between Gell-Mann and Einstein biographer Abraham Pais, who Gell-Mann once bitterly called "that little dwarf"). In terms of raw I.Q. the two New Yorkers certainly were equal to each other. It was the joint presence of these wunderkinder that made Caltech perhaps the most exciting place for theoretical physics in the 60s and 70s. Now most of the public believes Feynman won the contest, but that's probably because, as Gell-Mann put it, Feynman was inordinately fond of generating anecdotes about himself and making himself appear larger than life. The two worked together for a while and admired each other for the rest of their lives, but according to Gell-Mann he eventually got tired of what he thought was Feynman's preoccupation with self-promotion.

In some sense Gell-Mann was the perfect foil to Feynman's anecdote generator, just as Feynman was often the perfect foil to Gell-Mann's predilection for tossing out trivia. I would wager that Gell-Mann's quarks were at least as important as Feynman's quantum electrodynamics, laying the foundation for all the particle physics that followed, including the culmination of the efforts of many people in the Standard Model. Gell-Mann also made other important contributions to physics, including to current algebra and quantum chromodynamics. Ironically, famous rival as he was, it was Feynman who paid Gell-Mann the ultimate compliment: "Our knowledge of fundamental physics contains not one fruitful idea that does not carry the name of Murray Gell-Mann".

Gell-Mann would easily be Feynman's contender for the world's smartest man not only because he has racked up a tremendous amount of achievement in physics but because he also, in the words of his biographer George Johnson, seems to know everything about everything. Simply conquering physics was not enough for Gell-Mann, he wanted to conquer the depths of all human knowledge. His christening of quarks based on a remark from James Joyce's dense "Finnegan's Wake" was not a coincidence. The range of his intellectual facilities equaled that of Oppenheimer, and he can tell you as much about linguistics or classical history as he can about physics; it was his propensity to generously offer trivia about these topics that in part used to drive Feynman crazy. He is fluent in half a dozen languages and known for correcting native speakers' pronunciations of words from their own language. With such a prodigious command of the world's knowledge at his disposal, it's not surprising that he does not suffer fools gladly; he is known to walk out of meetings (like his august predecessor Wolfgang Pauli) if he thinks less of the speaker. I was not afraid of knocking on Freeman Dyson's door, but I would have to fortify my nerves with a few shots of gin before contemplating an encounter with Gell-Mann.

Regarding literature on or by Gell-Mann, you can do no better than George Johnson's "Strange Beauty" which along with James Gleick's "Genius" is the best physics biography I have ever read. Gell-Mann himself has found it notoriously painful to put pen to paper all his life and therefore it is no surprise to find that he almost disowned his own book - part scientific meditation, part memoir- after it was written. And yet I will recommend it warmly: "In "The Quark and the Jaguar" Gell-Mann ruminates across a vast range of time and length scales of the cosmos, from quarks to humans to the entire universe. It has sparkling and remarkably clear discussions of topics like algorithmic complexity and quantum electrodynamics and reading it feels akin to getting an intellectual workout in a swanky gym. With Gell-Mann holding forth on science and the universe, life is at least not dull.

And therefore the best tribute to the man with five brains would be a vodka martini, shaken with a generous helping of nature's fundamental forces and stirred with the ingredients of the cosmos, and held up with a full-throated cry of "Three quarks for Muster Mark!".